NPPNY Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 17:24):

Stats
Dzisiejszy wolumen	135.00
Średni wolumen	94.00
Kapitalizacja rynkowa	1.90B
EPS	$27.56 ( 2023-09-30 )
Następna data zysków	( $0 ) 2024-05-10
Last Dividend	$0.105 ( 2022-09-29 )
Next Dividend	$0 ( N/A )
P/E	12.38
ATR14	$0 (0.00%)

Nippon Shinyaku Co., Ltd. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Nippon Shinyaku Co., Ltd. Finanse

Annual	2023
Przychody:	$144.18B
Zysk brutto:	$88.20B (61.17 %)
EPS:	$338.70

FY	2023
Przychody:	$144.18B
Zysk brutto:	$88.20B (61.17 %)
EPS:	$338.70

FY	2022
Przychody:	$137.48B
Zysk brutto:	$87.29B (63.49 %)
EPS:	$370.97

FY	2021
Przychody:	$121.89B
Zysk brutto:	$71.93B (59.02 %)
EPS:	$76.84

Financial Reports:

No articles found.

Nippon Shinyaku Co., Ltd. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.105 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Nippon Shinyaku Co., Ltd. Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.36 - Stable (27.23%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.0575	2017-10-02
Last Dividend	$0.105	2022-09-29
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	11	--
Total Paid Out	$1.029	--
Avg. Dividend % Per Year	0.00%	--
Score	4.11	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.36
Div. Directional Score	10.00	--

Next Divdend (Est)
(2024-05-07)

$0 Estimate 0.00 %

Dividend Stability

0.09 Very Bad

Dividend Score

4.11

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
XNGSY	Ex Dividend Junior	2023-11-02	Annually	0.00%
MAORF	Ex Dividend Junior	2023-08-17	Sporadic	0.00%
CLCGY	Ex Dividend Junior	2023-06-29	Annually	0.00%
SONVY	Ex Dividend Knight	2023-06-14	Annually	0.00%
HAWPY	Ex Dividend Knight	2023-08-22	Semi-Annually	0.00%
AILLO	Ex Dividend Knight	2023-07-14	Semi-Annually	0.00%
NLCP	Ex Dividend Knight	2023-09-28	Quarterly	0.00%
CRRFY	Ex Dividend Junior	2023-06-06	Sporadic	0.00%
THVB	Ex Dividend Knight	2023-06-14	Semi-Annually	0.00%
HYPMY	Ex Dividend Knight	2023-07-06	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.164	1.500	6.72	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0974	1.200	6.75	8.10	[0 - 0.3]
returnOnEquityTTM	0.117	1.500	9.81	10.00	[0.1 - 1]
payoutRatioTTM	0.331	-1.000	6.69	-6.69	[0 - 1]
currentRatioTTM	5.92	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	4.17	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.11	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.00826	-1.500	9.86	-10.00	[0 - 0.6]
interestCoverageTTM	264.20	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	321.86	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	163.50	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.00953	-1.500	9.96	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.646	1.000	2.57	2.57	[0.2 - 0.8]
operatingProfitMarginTTM	0.226	1.000	7.47	7.47	[0.1 - 0.6]
cashFlowToDebtRatioTTM	10.59	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.593	0.800	9.38	7.50	[0.5 - 2]
Total Score				13.73

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	3.03	1.000	9.80	0	[1 - 100]
returnOnEquityTTM	0.117	2.50	9.88	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	163.50	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.0000649	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	321.86	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.331	1.500	6.69	-6.69	[0 - 1]
pegRatioTTM	0.000710	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.147	1.000	8.81	0	[0.1 - 0.5]
Total Score				6.36

Nippon Shinyaku Co., Ltd.

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. In addition, it researches, develops, and markets drugs in the areas of gynecology, otorhinolaryngology, and orthopedics. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, supplements, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.